Strategic partnerships Microbot Medical has actively pursued manufacturing and distribution collaborations, notably with Sanmina Corporation and Lovell Government Services, indicating strong opportunities for channel sales, contract manufacturing, and expanded access within federal and international healthcare systems.

Endovascular focus The LIBERTY Endovascular Robotic System is FDA-cleared and single-use with remote operation, positioning Microbot as a specialist in robotics-enabled endovascular procedures and creating upsell potential with hospitals seeking precision, safety, and efficiency gains in vascular interventions.

Financial readiness With funding around $92M and revenue in the low single-digit millions, there is a clear path for growth capital to scale commercial operations, expand sales territories (EMEA and beyond), and advance associated clinical evidence to accelerate adoption.

Recognition leverage Award momentum from the Surgical Robotics Industry Awards and active presence at robotic surgery events enhances credibility for outreach to hospital procurement and GPOs, offering a springboard for demonstrations, trials, and policy-driven adoption.

Market expansion Ongoing international commercial expansion plans, including a newly appointed VP of Sales for EMEA and partnerships to broaden access across federal networks, present targeted opportunities to identify institutional buyers, leverage reimbursement pathways, and accelerate multi-site deployment.